Yssel, J., O’Neill, E., Nolan, Y., Connor, T., & Harkin, A. (2018). Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2018.01.004 (Original work published 2018)

, Gillan, C., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & ’Keane, O. , V. Psychedelic Therapy’s Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Frontiers in Psychiatry, 12, 800072. https://doi.org/10.3389/fpsyt.2021.800072 (Original work published 2021)